Transcription of Executive Summary SAGE October 2017, …
{{id}} {{{paragraph}}}
Example: barber
Executive Summary SAGE October 2017, …
1 Executive Summary SAGE October 2017, pneumococcal conjugate vaccine Session Introduction Currently, WHO has recommended the use of either a 10-valent or 13-valent pneumococcal conjugate vaccine (PCV10 and PCV13, respectively), for all infants worldwide. For routine immunization, WHO has recommended that PCV can be administered using either a 2p+1 or 3p+0 schedule, though 3p+1 schedules are also used in some countries[1]. A total of 141 countries have introduced PCV into their national immunization program, and 7 out of the 10 countries with the highest pneumococcal disease burden have recently introduced the vaccine [2]. Since the introduction of the first PCV (PCV7) in 2000, global reductions in pneumococcal disease burden in children under 5 years of age have been observed. The number of deaths attributable to pneumococcal disease has been halved since 2000 among HIV negative children under 5, from approximately 600,000 to 294,000 deaths in 2015.
1 . Executive Summary SAGE October 2017, Pneumococcal Conjugate Vaccine Session . 1.0 Introduction Currently, WHO has recommended the use of either a 10-valent or 13-valent pneumococcal
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
PCV13 vs PPSV23: Which to Give and, Valent pneumococcal conjugate vaccine, WORLD HEALTH ORGANIZATION, Pneumococcal, Pneumococcal Polysaccharide Clinical Guidelines, Vaccine, Saving Lives: Pneumococcal Disease: Integrating, Vaccine Names and Abbreviations, Vaccine Names and Abbreviations Vaccine, Vaccine Acronyms & Abbreviations for Providers